Sanritatug

萨瑞妥塔单抗

Report date: 2026/04/28 20:00:22

Base Information

Drug NameSanritatug
Drug Alias NameSG301 SC注射液SG-301SG301
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Chimeric monoclonal antibody
Mechanisms of ActionAnti-CD38
TargetsLymphocyte differentiation antigen CD38
Therapy Area/IndicationsRejection of renal transplantationLupus Erythematosus, SystemicThrombocytopenia +[7] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaPhase 3 Clinical
Originator CompaniesHangzhou Shangjian Biotechnology Co Ltd
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesThe Children'S Hospital, Zhejiang University School Of MedicineHangzhou Shangjian Biotechnology Co Ltd
Inactive CompaniesN/A
Active IndicationsRejection of renal transplantationLupus Erythematosus, SystemicThrombocytopenia +[7] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A